Sagimet Biosciences closes USD 115 million underwritten Series A common stock, pre-funded warrant offering

By Public Technologies
  • Sagimet Biosciences closed an underwritten offering of 8,750,010 shares of Series A common stock priced at USD 10.00.
  • Investors also bought pre-funded warrants to purchase 2,750,010 Series A common shares at USD 9.9999 each.
  • Pre-funded warrants carry a USD 0.0001 exercise price, exercisable immediately.
  • Gross proceeds totaled about USD 115 million before underwriting discounts, commissions, and offering expenses.
  • Net proceeds earmarked for Phase 3 denifanstat acne trial, pre-launch work, TVB-3567 through Phase 2 topline, other R&D, general purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011631PRIMZONEFULLFEED9838257) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.